Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: | Dermatology | Immunology | Rheumatology | Family Medicine
Search Medical Condition
Psoriatic Arthritis Clinical Trials
A listing of Psoriatic Arthritis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found (72) clinical trials
Psoriatic Arthritis – Inadequate response to biologic DMARDs
A research study is evaluating an investigational medication for psoriatic arthritis This research study may be an option if you: Are at least 18 years of age Have a diagnosis of active psoriatic arthritis for at least 6 months Have a history of or current plaque psoriasis Have at least ...
A Double-Blind, Randomized controlled study of Etanercept and Methotrexate in combination or as Monotherapy in subjects with Psoriatic Arthritis
This study of Etanercept and Methotrexate compared to Etanercept alone and Methotrexate alone will last up to 52 weeks. Qualified participants may receive compensation for study-related travel.
A Phase III, Randomized, Double-blind, Placebo-controlled Study of Subcutaneous Secukinumab in Autoinjectors, to Demonstrate Efficacy at 24 Weeks and Long Term Safety and Efficacy up to 3.5 Years in Subjects With Active Psoriatic Arthritis
The purpose of this study is to provide 24 - 52 week efficacy, safety and tolerability data, as well as up to 3.5-year efficacy, safety and tolerability data in subjects with active Psoriatic Arthritis despite current or previous nonsteroidal anti-inflammatory drug (NSAID), disease-modifying antirheumatic drug (DMARD) therapy and/or previous anti-tumor ...
PSA-006
A Phase 3B, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) Monotherapy in Subjects with Active Psoriatic Arthritis
A 52 week, multicenter study to assess the time course of response to secukinumab on joint inflammation using Power Doppler Ultrasonography in patients with active psoriatic arthritis (PsA)
Study of the application of Power Doppler Ultrasonography (PDUS) to measure response to secukinumab treatment in patients with active psoriatic arthritis (PsA)
A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) - SELECT - PsA 1
This is a Phase 3 multicenter study that includes two periods. Period 1 is designed to compare the safety, tolerability, and efficacy of ABT-494 Dose A once daily (QD) and Dose B QD versus placebo and versus adalimumab every other week (eow) in participants with moderately to severely active Psoriatic ...
A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD)
This is a Phase 3 multicenter study that includes two periods. Period 1 is designed to compare the safety, tolerability, and efficacy of ABT-494 Dose A once daily (QD) and Dose B QD versus placebo in participants with moderately to severely active Psoriatic Arthritis (PsA) who have an inadequate response ...
A 52 Week, Multicenter Study To Assess The Time Course Of Response To Secukinumab On Joint Inflammation Using Power Doppler Ultrasonography In Patients With Active Psoriatic Arthritis.
A 52 Week, Multicenter Study To Assess The Time Course Of Response To Secukinumab On Joint Inflammation Using Power Doppler Ultrasonography In Patients With Active Psoriatic Arthritis.
A Randomized, Double-Blind, Study Comparing ABT-494 To Placebo And To Humira In Subjects With Active Psoriatic Arthritis That Has/Had A History Of Inadequate Response To At Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD).
A Randomized, Double-Blind, Study Comparing ABT-494 To Placebo And To Humira In Subjects With Active Psoriatic Arthritis That Has/Had A History Of Inadequate Response To At Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD).
A Phase 3, Randomized, Double-Blind Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)
The purpose of this study is to evaluate the safety and efficacy of risankizumab in the patients with moderately to severely active psoriatic arthritis (PsA).
